A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

296

Participants

Timeline

Start Date

August 19, 2013

Primary Completion Date

January 13, 2017

Study Completion Date

May 5, 2017

Conditions
Glioblastoma
Interventions
DRUG

Bevacizumab

Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).

DRUG

Lomustine

Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m\^2 PO Q6W, with a cap of 200 mg per dose.

DRUG

Placebo

Placebo will be administered via IV infusion, in a formulation matched to bevacizumab, Q2W after randomization.

RADIATION

Radiotherapy

Radiotherapy will be administered for a total dose of 60 Gray (Gy), administered in 2-Gy fractions, 5 days per week for 6 weeks during first-line treatment.

DRUG

Temozolomide

Temozolomide will be administered orally (PO) as 75 mg/m\^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m\^2 per day for the first 5 days of Cycle 1, then 200 mg/m\^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.

DRUG

SOC Agent

The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.

Trial Locations (64)

1090

Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Vienna

1100

Kaiser-Franz-Josef-Spital; Neurologische Abteilung, Vienna

1303

MBAL Serdika EOOD, Sofia

4020

Kepler Universitätsklinikum GmbH - Neuromed Campus; Innere Medizin mit Neuroonkologie, Linz

5020

Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg

6020

Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie, Innsbruck

8036

Medizinische Universität Graz; Universitätsklinik für Neurologie, Graz

10000

Clinical Hospital Centre Zagreb, Zagreb

10126

Azienda Ospedaliera Le Molintte di Torino; Dipartimento Di Neurologia - Oncologia, Turin

13385

Hopital de La Timone - CHU de Marseille; Service de neuro-oncologie - Hôpital Adultes - 12ème étage, Marseille

14004

Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba

14033

Hopital Cote De Nacre; Unite Neurologie Generale, Caen

14564

Agioi Anargyroi Anticancer Hospital; Radiotherapeutic Clinic, Kifissia

15123

Hygeia Hospital, Marousi

20014

IInstituto Oncologico de San Sebastian, Oncologikoa; Servicio de Oncologia, Donostia / San Sebastian

20133

Fondazione IRCCS Istituto Neurologico C. Besta; Neuro-oncologia Sperimentale e Terapia Genica, Milan

21079

Centre Georges Francois Leclerc; Oncologie 3, Dijon

25030

HOPITAL JEAN MINJOZ; Oncologie, Besançon

28034

Hospital Ramon y Cajal; Servicio de Oncologia, Madrid

28040

Hosp. Clinico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid

28046

Hospital Universitario La Paz; Servicio de Oncologia, Madrid

28050

HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid

29010

Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Málaga

31059

Hopital Purpan, Toulouse

31380

Kocaeli University Faculty of Medicine; Medical oncology, İzmit

33075

Hopital Saint Andre; Département de Radiothérapie Et D'Oncologie Médicale, Bordeaux

35128

IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padua

35340

Dokuz Eylul Uni ; Medical Oncology, Izmir

37007

Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca

40133

Ospedale Bellaria; U.O. Oncologia Medica, Bologna

48903

Hospital de Cruces; Servicio de Oncologia, Bilbao

50406

Tartu University Hospital; Clinic of Hematology and Oncology, Tartu

54000

Hôpital Central; Departement de Neuro-Oncologie, Nancy

58185

Universitetssjukhuset; Onkologkliniken, Linköping

59037

Hopital Roger Salengro; Service de Neurologie, Lille

69677

Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron

75185

Akademiska sjukhuset, Onkologkliniken, Uppsala

75651

Hopital Pitié Salpétrière - CHU; Service de neurologie 2 - Mazarin, Paris

93009

Hopital Avicenne; Neurologie, Bobigny

400015

Institut Oncologic Ion Chiricuta; Departament Radioterapie, Cluj-Napoca

540142

Spital Clinic Judetean Mures; Oncologie, Târgu Mureş

T2N 4N2

Tom Baker Cancer Centre; Dept of Medicine, Calgary

H3A 2B4

McGill University; Montreal Neurological Institute; Oncology, Montreal

546 29

Papageorgiou General Hospital; Medical Oncology, Thessaloniki

00144

IFO - Istituto Regina Elena; Oncologia Medica, Rome

LV-1038

Riga East Clinical University hospital, Clinic Gailezers, Dept of Neurosurgery, Riga

3000-075

IPO de Coimbra; Servico de Oncologia Medica, Coimbra

1649-035

Hospital de Santa Maria; Servico de Oncologia Medica, Lisbon

4200-319

Hospital de Sao Joao; Servico de Oncologia, Porto

022328

Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, Bucharest

07014

Hospital Universitario Son Espases; Servicio de Oncologia, Palma de Mallorca

08916

Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona

06080

Hospital Universitario Infanta Cristina; Servicio de Oncologia, Badajoz

08003

Hospital del Mar; Servicio de Oncologia, Barcelona

08907

Hospital Duran i Reynals; Oncologia, Barcelona

901 85

Norrlands Universitetssjukhus; Cancer Centrum, Umeå

01060

Adana City Hospital, Medical Oncology, Adana

06490

Baskent Universitesi Tıp Fakultesi; Ic Hastalıkları Anabilim Dalı Tıbbi Onkoloji Bilim Dalı, Ankara

BS2 8ED

Bristol Haematology and Oncology Centre, Bristol

CB2 2QQ

Addenbrookes Hospital; Dept of Oncology, Cambridge

N7 9NH

University College Hospital; Department of Oncology, London

M2O 4BX

Christie Hospital Nhs Trust; Medical Oncology, Manchester

SM2 5PT

Royal Marsden Hospital; Dept of Medical Oncology, Sutton

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01860638 - A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | Biotech Hunter | Biotech Hunter